- freely available
- re-usable
Mar. Drugs 2012, 10(4), 793-811; doi:10.3390/md10040793
Review
Fucanomics and Galactanomics: Marine Distribution, Medicinal Impact, Conceptions, and Challenges
Program of Glycobiology, Institute of Medical Biochemistry, and University Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, 21941-590, Brazil
Received: 21 February 2012; in revised form: 21 March 2012 / Accepted: 22 March 2012 / Published: 29 March 2012
(This article belongs to the Special Issue Marine Glycoconjugates)
The original version is still available [242 KB, uploaded 29 March 2012 10:09 CEST]
Abstract: Glycomics turned out to be a very extensive project where its subdivision is consequently emerging. This is seen by the growing number of terminologies used to define subprojects concerning particular classes of bioactive carbohydrates. Sulfated fucans (SFs) and sulfated galactans (SGs) are relatively new classes of sulfated polysaccharides (SPs) that occur mostly in marine organisms, and exhibit a broad range of medicinal effects. Their structures are taxonomically dependent, and their therapeutic actions include benefits in inflammation, coagulation, thrombosis, angiogenesis, cancer, oxidation, and infections. Some red algae, marine angiosperm and invertebrates express SPs of unique structures composed of regular repeating oligomeric units of well-defined sulfation patterns. This fine pattern of structural regularity is quite rare among any naturally occurring long SPs, and enables accurate structure-biofunction correlations. Seeing that, fucanomics and galactanomics may comprise distinguished glycomics subprojects. We hereby discuss the relevance that justifies the international recognition of these subprojects in the current glycomics age associated with the beneficial outcomes that these glycans may offer in drug development.
Keywords: fucanome; fucanomics; galactanome; galactanomics; glycome; glycomics; sulfated fucan; sulfated galactan
Article Statistics
Click here to load and display the download statistics.Cite This Article
MDPI and ACS Style
Pomin, V.H. Fucanomics and Galactanomics: Marine Distribution, Medicinal Impact, Conceptions, and Challenges. Mar. Drugs 2012, 10, 793-811.
AMA StylePomin VH. Fucanomics and Galactanomics: Marine Distribution, Medicinal Impact, Conceptions, and Challenges. Marine Drugs. 2012; 10(4):793-811.
Chicago/Turabian StylePomin, Vitor H. 2012. "Fucanomics and Galactanomics: Marine Distribution, Medicinal Impact, Conceptions, and Challenges." Mar. Drugs 10, no. 4: 793-811.
Mar. Drugs
EISSN 1660-3397
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert
